Rationally Designing Protein Degrader Drugs of the Future

Plexium is a clinical-stage biotechnology company pioneering precision medicine for some of the most challenging or “undruggable” targets.

The company’s differentiated platform harnesses proprietary discovery technologies to develop a pipeline of targeted protein degrader (TPD) therapeutics, including first- and best-in-class selective molecular glues and direct degraders.

Plexium’s programs offer unique advantages over traditional small molecules and biologics, particularly in oncology.